Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors

Journal of Medicinal Chemistry

Volumn 48, Issue 11, 2005, Pages 3808-3815

  Korhonen, Laura E ^a   Rahnasto, Minna ^a   Mähönen, Niina J ^a   Wittekindt, Carsten ^a   Poso, Antti ^a   Juvonen, Risto O ^a   Raunio, Hannu ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

1 CHLORONAPHTHALENE; 1 METHYLNAPHTHALENE; 1 NAPHTHOL; 1,2 DIMETHYLNAPHTHALENE; 1,3 DIMETHYLNAPHTHALENE; 1,4 DIMETHYLNAPHTHALENE; 1,5 DICHLORONAPHTHALENE; 1,5 DIMETHYLNAPHTHALENE; 1,6 DIMETHYLNAPHTHALENE; 1,7 DIMETHYLNAPHTHALENE; 2 (4 TOLYL)ETHYLAMINE; 2 BENZOXAZOLONE DERIVATIVE; 2 CHLOROBIPHENYL DERIVATIVE; 2 COUMARONE; 2 ETHYLNAPHTHALENE; 2 FLUORONAPHTHALENE; 2 INDANONE; 2 METHOXYNAPHTHALENE; 2 METHYLNAPHTHALENE; 2 NAPHTHOL; 2,4 DIMETHYLQUINOLINE; 2,6 DIMETHYLNAPHTHALENE; 2,6 DIMETHYLQUINOLINE; 2,7 DIMETHYLNAPHTHALENE; 2,7 DIMETHYLQUINOLINE; 3 METHYLISOQUINOLINE; 3 METHYLQUINOLINE; 4 CHLOROBIPHENYL DERIVATIVE; 4 METHOXYFURAN 2(5H) ONE; 4,6 DIMETHYL ALPHA PYRONE; ANISALDEHYDE; BIPHENYL DERIVATIVE; BUTYLBENZYL DERIVATIVE; BUTYLCYCLOHEXANE; COTININE; CYTOCHROME P450 1A2; CYTOCHROME P450 INHIBITOR; DELTA DECANOLACTONE; DIHYDROBENZOFURAN DERIVATIVE; EPSILON CAPROLACTONE; ETHOXYRESORUFIN; GAMMA CAPROLACTONE; GAMMA DECANOLACTONE; GAMMA HEPTALACTONE; GAMMA LAUROLACTONE; GAMMA NONANOIC LACTONE; GAMMA PHENYL GAMMA BUTYROLACTONE; GAMMA VALEROLACTONE; INDAN DERIVATIVE; KETOCONAZOLE; LACTONE; NAPHTHALENE; NICOTINE; QUERCETIN; QUINALDINE; QUINIDINE; QUINOLINE DERIVATIVE; SULFAPHENAZOLE; TRANYLCYPROMINE; UNCLASSIFIED DRUG; UNDECANOIC DELTA LACTONE; UNDECANOIC GAMMA LACTONE;

ARTICLE; COMPARATIVE MOLECULAR FIELD ANALYSIS; COMPUTER MODEL; DEALKYLATION; DRUG POTENCY; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME INHIBITOR INTERACTION; IC 50; PREDICTION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; THREE DIMENSIONAL IMAGING;

CYTOCHROME P-450 CYP1A2; ENZYME INHIBITORS; LACTONES; MODELS, MOLECULAR; MOLECULAR CONFORMATION; NAPHTHALENES; OXAZINES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; QUINOLINES;

EID: 20144370197     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0489713     Document Type: Article

References (26)

1. Eaton, D. L.; Gallagher, E. P.; Bammler, T. K.; Kunze, K. L. Role of cytochrome P4501A2 in chemical carcinogenesis: Implications for human variability in expression and enzyme activity. Pharmacogenetics 1995, 5, 259-274.
2. Guengerich, F.; Parikh, A.; Turesky, R.; Josephy, P. Inter-individual differences in the metabolism of environmental toxicants: Cytochrome P450 1A2 as a prototype. Mutat. Res. 1999, 428, 115-124.
3. Butler, M. A.; Iwasaki, M.; Guengerich, F. P.; Kadlubar, F. F. Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc. Natl. Acad. Sci. U.S.A. 1989, 86, 7696-7700.
4. Robson, R. A.; Matthews, A. P.; Miners, J. O.; McManus, M. E.; Meyer, U. A.; Hall, P. M.; Birkett, D. J. Characterisation of theophylline metabolism in human liver microsomes. Br. J. Clin. Pharmacol. 1987, 24, 293-300.
5. Sesardic, D.; Boobis, A. R.; Murray, B. P.; Murray, S.; Segura, J.; de la Torre, R.; Davies, D. S. Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. Br. J. Clin. Pharmacol. 1990, 29, 651-663.
6. Brosen, K.; Skjelbo, E.; Rasmussen, B. B.; Poulsen, H. E.; Loft, S. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem. Pharmacol. 1993, 45, 1211-1214.
7. Pelkonen, O.; Maenpaa, J.; Taavitsainen, P.; Rautio, A.; Raunio, H. Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica 1998, 28, 1203-1253.
8. Ekins, S.; de Groot, M. J.; Jones, J. P. Pharmacophore and three-dimensional quantitative structure activity relationship methods for modeling cytochrome p450 active sites. Drug Metab. Dispos. 2001, 29, 936-944.
9. Fuhr, U.; Strobl, G.; Manaut, F.; Anders, E. M.; Sorgel, F.; Lopez-de-Brinas, E.; Chu, D. T.; Pernet, A. G.; Mahr, G.; Sanz, F. Quinolone antibacterial agents: Relationship between structure and in vitro inhibition of the human cytochrome P450 isoform CYP1A2. Mol. Pharmacol. 1993, 43, 191-199.
10. Sanz, F.; Lopez-de-Brinas, E.; Rodriques, J.; Manaut, F. Theoretical study on the metabolism of caffeine by cytochrome P-450 1A2 and its inhibition. Quant. Struct.-Act. Relat 1994, 13, 281-284.
11. Lee, H.; Yeom, H.; Kim, Y. G.; Yoon, C. N.; Jin, C.; Choi, J. S.; Kim, B. R.; Kim, D. H. Structure-related inhibition of human hepatic caffeine N3-demethylation by naturally occurring flavonoids. Biochem. Pharmacol. 1998, 55, 1369-1375.
12. De Rienzo, F.; Fanelli, F.; Menziani, M. C.; De Benedetti, P. G. Theoretical investigation of substrate specificity for cytochromes P450 IA2, P450 IID6 and P450 IIIA4. J. Comput.-Aided Mol. Des. 2000, 14, 93-116.
13. Lozano, J. J.; Pastor, M.; Cruciani, G.; Gaedt, K.; Centeno, N. B.; Gago, F.; Sanz, F. 3D-QSAR methods on the basis of ligand-receptor complexes. Application of COMBINE and GRID/GOLPE methodologies to a series of CYP1A2 ligands. J. Comput.-Aided Mol. Des. 2000, 14, 341-353.
14. Lewis, D. F. V. On the recognition of mammalian microsomal cytochrome P450 substrates and their characteristics. Biochem. Pharmacol. 2000, 60, 293-306.
15. Moon, T.; Chi, M. H.; Kim, D.; Yoon, C. N.; Choi, Y. Quantitative structure-activity relationship (QSAR) study of flavonoid derivatives for inhibition of cytochrome P450 1A2. Quant. Struct.-Act. Relat. 2000, 19, 257-263.
16. Pastor, M.; Cruciani, G.; Clementi, S. Smart region definition: A new way to improve the predictive ability and interpretability of three-dimensional quantitative structure-activity relationships. J. Med. Chem. 1997, 40, 1455-1464.
17. Turpeinen, M.; Uusitalo, J.; Jalonen, J.; Pelkonen, O. Multiple P450 substrates in a single run: rapid and comprehensive in vitro interaction assay. Eur. J. Pharm. Sci. 2005, 24, 123-132
18. Dai, R.; Pincus, M. R.; Friedman, F. K. Molecular modeling of mammalian cytochrome P450s. Cell. Mol. Life Sci. 2000, 57, 487-499.
19. Juvonen, R. O.; Gynther, J.; Pasanen, M.; Alhava, E.; Poso, A. Pronounced differences in inhibition potency of lactone and non-lactone compounds for mouse and human coumarin 7-hydroxylases (CYP2A5 and CYP2A6). Xenobiotica 2000, 30, 81-92.
20. Asikainen, A.; Tarhanen, J.; Poso, A.; Pasanen, M.; Alhava, E.; Juvonen, R. O. Predictive value of comparative molecular field analysis modelling of naphthalene inhibition of human CYP2A6 and mouse CYP2A5 enzymes. Toxicol. in Vitro 2003, 17, 449-455.
21. Rahnasto, M.; Raunio, H.; Poso, A.; Wittekindt, C.; Juvonen, R. O. Quantitative structure-activity relationship analysis of inhibitors of the nicotine metabolizing CYP2A6 enzyme. J. Med. Chem. 2005, 48, 440-449.
22. Ekins, S.; Berbaum, J.; Harrison, R. K. Generation and validation of rapid computational filters for cyp2d6 and cyp3a4. Drug Metab. Dispos. 2003, 31, 1077-1080.
23. Erhardt, P. W. A human drug metabolism database: Potential roles in the quantitative predictions of drug metabolism and metabolism-related drug-drug interactions. Curr. Drug Metab. 2003, 4, 411-422.
24. Burke, M. D.; Thompson, S.; Elcombe, C. R.; Halpert, J.; Haaparanta, T.; Mayer, R. T. Ethoxy-, pentoxy- and benzyloxyphenoxazones and homologues: A series of substrates to distinguish between different induced cytochromes P-450. Biochem. Pharmacol. 1985, 34, 3337-3345.
25. Wade, R. C.; Clark, K. J.; Goodford, P. J. Further development of hydrogen bond functions for use in determining energetically favorable binding sites on molecules of known structure. 1. Ligand probe groups with the ability to form two hydrogen bonds. J. Med. Chem. 1993, 36, 140-147.
26. Baroni, M.; Constantino, G.; Cruciani, G.; Riganelli, D.; Valigi, R.; Clementi, S. Generating optimal linear PLS estimations (GOLPE): An advanced chemometric tool for handling 3D-QSAR problems. Quant. Struct.-Act. Relat. 1993, 12, 9-20.